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Severity of pain (BPI-item-3) was statistically associated with
total annual health costs; €1255 (932), €1473 (1198) and
€1950 (1391) for mild, moderate and severe pain respectively,
p = 0.017. Walking (FIQ1g) and work/domestic (BPI5d) inter-
ference were positive predictors for per patient annual drug
costs, while pain problems and 12-month health state change
(EQ-5D items 4 and 6) were negative predictors (R2 = 0.283,
p < 0.001). CONCLUSION: In the primary care setting, annual
per patient total direct health cost of Fibromyalgia showed
weak but statistically signiﬁcant association with patient disease
interference and severity of pain. Less drug costs could be asso-
ciated with poorer outcomes in term of health state change and
level of pain.
OBESITY—Clinical Outcomes Studies
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OBJECTIVES: To describe the association between obesity and
costs and use of antipsychotic drugs (APDs) in patients seen by
seven Spanish primary care teams (PCTs), under usual medical
practice. METHODS: A retrospective, multicenter study was
made with patients receiving APD treatment during year 2005.
Obesity was considered according to W.H.O. as a body mass
index (BMI) > 30 kg/m2. Main measurements included APD
consumption, sociodemographics, comorbidity/episodes, Charl-
son index (severity), and costs (semi-ﬁxed and variable, visits,
diagnostic/therapeutic procedures, referrals and drugs). Descrip-
tive statistics, logistic regression model and analysis of covari-
ance (ANCOVA) with Bonferroni correction were applied.
RESULTS: A total of 42,437 patients (age: 50.9  17.8 years,
women: 59.9%) were included in the analysis. Obesity was
present in 27.3% [CI: 26.9–27.7%]), with a 1.3% receiving
APDs (typical: 48.8%, atypical: 51.2%; p = NS). Patients with
obesity showed higher annual average of episodes (7.0  4.0
vs. 5.5  3.6), visits (12.1  9.8 vs. 9.1  8.5) and severity
(0.5  0.7 vs. 0.3  0.6), p < 0.001. In the logistic regression
analysis, obesity was related to APD use (OR = 1.5; CI: 1.3–
1.8), hypertension (OR = 2.4; CI: 2.2 2.5), diabetes (OR = 1.4;
CI: 1.3–1.5) and dyslipidemia (OR = 1.3; CI: 1.2–1.4),
p < 0.001 in all cases. After adjusting, BMI was slightly higher
in subjects on APD; 27.8 kg/m2 vs. 27.4 kg/m2, p = 0.002.
Mean crude and adjusted (age, gender and comorbidities)
annual costs were signiﬁcantly higher in obese patients than
in non obese; €980.89  1,467.49 vs. €637.64  1,244.49,
p < 0.001, and €810.88 vs. €693.79, p < 0.001 respectively. All
components of per patient per year costs were higher in the
group of obese patients, p < 0.0001. CONCLUSION: Obesity
was associated with the use of APDs and the presence of hyper-
tension, diabetes and dyslipidemia. No differences were found
between using typical or atypical APDs. Obese patients pre-
sented more comorbidity, use of health resources and associated
costs.
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OBJECTIVES: Clinical trials have demonstrated that rimona-
bant leads to signiﬁcant improvements in cardiometabolic risk
factors, including weight, waist circumference, lipids, and fasting
glucose. This study translates these beneﬁts into expected out-
comes when rimonabant is administered to adults with dyslipi-
demia and a BMI>27 kg/m2 in addition to diet and exercise.
METHODS: A discrete event simulation was developed to
project outcomes in individuals at increased cardiometabolic
risk. Data from the Health Survey of England are used to create
simulated adults free of cardiovascular disease (CVD) and dia-
betes but who are overweight or obese and have either elevated
triglycerides or low HDL. Equations derived from the RIO trials
are used to calculate changes in individual cardiometabolic risk
factors as a function of time, treatment and baseline risk factors.
Treatments considered are diet and exercise alone or with the
addition of rimonabant 20mg. The simulation determines when
individuals develop CVD, diabetes, or microvascular disease
(MVD) using published equations from Framingham, UKPDS
and the San Antonio Heart Study. RESULTS: After one year,
simulated patients on rimonabant lose an average of 4.4 kg com-
pared to only 0.4 kg with diet and exercise alone. On average
HDL levels increase by 0.07 mmol/L more with rimonabant;
triglyceride levels fall by 0.27 mmol/L more. Over their lifetimes,
1000 rimonabant users experience 9 fewer CVD events, live 66
years longer, and avoid 334 years with diabetes. MVD events fall
by 30. Extending treatment to 10 years results in 11% fewer
CVD events and life expectancy gains of 234 years compared to
one year of treatment. CONCLUSION: These results suggest
that in overweight or obese patients with dyslipidemia, cardi-
ometabolic risk factor improvements associated with rimona-
bant, which extend beyond those expected with diet and exercise
alone, could translate to concrete health gains by preventing or
delaying diabetes, MVD and acute CVD.
OBESITY—Methods and Concepts
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OBJECTIVES: The WinBUGS software is a powerful tool to
analyze data in the framework of the bayesian theory and has
recently been shown useful in developing complex probabilistic
Markov models. Despite some clear advantages, this technique
has not been fully exploited in health economic evaluations. We
developed a cost-utility and budget impact analysis of the use of
orlistat in Italian obese patients through this innovative model-
ling approach. METHODS: A probabilistic Markov model has
been developed to simulate outcomes of the obese Italian popu-
lation after four years of orlistat treatment plus six years of
follow-up. The efﬁcacy of the treatment derives from the
XENDOS study. The model integrates a Framingham Heart
Study-based algorithm to estimate cardiovascular risk. The
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analysis is made in the societal cost perspective, adding direct
medical costs charged both on the National Health Service and
the patient, since orlistat is not reimbursed. Costs and health
beneﬁts are discounted at a 3.5% annual rate. RESULTS: The
treatment with orlistat of the Italian obese population (estimated
in more than 4 million subjects), produces an estimated average
increase in quality-adjusted life expectance of 0.05 (0.035–
0.065) QALY/patient, an estimated reduction of cardiovascular
events and diabetes onsets at an estimated overall increased cost
(based on the current orlistat public price) of about 12 (1.7–13.7)
million Euro in 10 years. On the Impaired Glucose Tolerance
(IGT) patients subgroup (283,000 people), the beneﬁts are rela-
tively larger, and they come at an increased cost of 608 (-1.6–
918) thousands Euro. Estimated average (95% CI) cost-utility
incremental ratios are 60.8 (9.2–84.5) and 16.34 (-43.5–27.54)
thousand Euro/QALY for the whole cohort and the IGT sub-
population, respectively. CONCLUSION: Orlistat shows a good
pharmacoeconomic proﬁle, especially in IGT patients, with a
cost-utility of 16.340 Euro/QALY. This value is lower than that
of several therapeutic strategies commonly accepted in developed
countries.
POB4
GEMCAS MODEL—A DECISION ANALYTIC MODEL
ASSESSINGTHE COST-EFFECTIVENESS OFTREATMENTS FOR
OBESITY AND ASSOCIATED CARDIOVASCULAR
RISK FACTORS
Aidelsburger P1, Fuchs SM1, Hessel F2, Ulle T1,Wasem J3
1CAREM GmbH, Sauerlach, Germany, 2Sanoﬁ-Aventis, Berlin,
Germany, 3University of Duisburg-Essen, Essen, Germany
OBJECTIVES: Obesity, hypertension and dyslipidemia (low
HDL-cholesterol, high triglycerides) are known risk factors (RF)
for the development of cardiovascular diseases and diabetes mel-
litus type 2 (DM). The aim of the study was to develop a decision
analytic model as a tool to assess the cost-effectiveness of
treatment options of obesity and associated cardiovascular risk
factors. METHODS: As part of the German Metabolic and
Cardiovascular Risk Project GEMCAS a decision analytic model
from the German payer’s perspective was developed. RESULTS:
The model has a cycle length of one year and consists of nine
health states (HS): (HS1) DM without complications and no
further RF; (HS2) DM without complications and one further RF
(HS3) DM without complications and 2–4 further RF (HS4) DM
with microvascular complications (HS5) DM with macrovascu-
lar complications (HS6) healthy (HS7) 1–4 RF (HS8) post myo-
cardial infarction or stroke (HS9) death. Annual costs have been
assessed for each health state as well as for transitions due to
myocardial infarction or stroke: (HS1) 626 Euro (HS2) 794 Euro
(HS3) 962 Euro (HS4) 6.276 Euro (HS5) 3.633 Euro (HS6), 0
Euro (HS7), 336 Euro (HS8) 1.710 Euro, transition costs for
myocardial infarction are 4.560 Euro and for stroke 4.780 Euro.
Target population has a deﬁned risk proﬁle and transition prob-
abilities are calculated using the Framingham Risk Equation for
myocardial infarction and stroke. Additionally an independent
effect of obesity according to the INTERHEART study was
assumed. The development of DM was calculated based on the
risk equation from San Antonio Heart Study. CONCLUSION:
The presented model is a valuable tool to assess the cost-
effectiveness of different treatments options and can be adopted
for new interventions easily.
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OBJECTIVES: Given the increasing frequency of obesity and the
costs associated with it, it is vital to determine which interven-
tions are effective and cost-effective versus the alternatives. A
crucial step in both cases is a critical appraisal of the literature.
This study examined the quality of economic evaluations (EE)
of obesity interventions using a quantitative approach.
METHODS: Economic evaluations were selected using the NHS
Economic Evaluations Database (NHS EED, York UK)(1995–
2006). Quality was based on the method by Chiou (2003)
because its development involved many health economists and it
provides an overall quality score (range: -1100) using 16 criteria.
Associations between study characteristics and quality were
examined using regression analysis. Characteristics included
publication year, type of intervention (including diet, behaviour,
medicine, surgery, combined intervention), source of effective-
ness data (single study, literature review), country of evaluation,
and source of funding. RESULTS: Thirty-four EEs were identi-
ﬁed and all of them fulﬁlled only some criteria. The most
common weaknesses were no discussion of potential biases and
inappropriate time horizon or discounting method. Mean overall
score was 52 (range: 24–76, SD: 13). Recent EEs were better than
older ones (+1.5 points/year) and European EEs were better (15
points) than non-European ones. Source of effectiveness data and
source of funding were not associated with quality after adjust-
ment for year and country. Type of intervention was never asso-
ciated with quality. CONCLUSION: The average quality of EEs
seems moderate given a score of 52/100. There is much room for
improvement and examination of individual criteria is indispens-
able in achieving this. Determination of overall quality scores is
not an adequate substitute for a critical appraisal. Sometimes a
single weakness in a “very good” EE can be fatal and render
cost-effectiveness estimates useless. In contrast, elements of
a “poor” EE can be valuable when determining the cost-
effectiveness of an intervention.
PAIN—Clinical Outcomes Studies
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OBJECTIVES: Despite being a common problem, there is no
published epidemiological data on pain in Turkey. This large scale
survey had the main objective of demonstrating the incidence of
acute pain, but also sought to explore how individuals perceive
their pain, the impact it had on their lives, their perception of the
attitudes of others towards their pain, treatments received and the
adequacy of treatment. METHODS: Screening interviews identi-
ﬁed respondents aged 18 years with acute pain, for in-depth
interviews. It addressed the following aims: a) estimating the
incidence of acute pain in Turkey; b) quantifying causes of acute
pain; c) exploring the demographics of acute pain; d) exploring the
impact of acute pain on individual’s quality of life and daily
activities e) understanding current treatment practices.RESULTS:
Six percent of the respondents had acute pain. Sixty-seven percent
of the 313 respondents willing to participate, had pain due to
another disease, 33% of them did not have any disease related to
Abstracts A463
